KyungDong Pharm home
Prescription Medicines

Famclovir Tab.

Product Category
antiviral drugs
Active Ingredients
Famciclovir
Appearance
A white, round, film-coated tablet.
Reimbursement Code
648102240
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
- Active ingredient: Famciclovir (USP)----250mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, sodium starch glycolate, propylene glycol, hydroxypropyl cellulose, hypromellose 2910

2. Effectiveness
1. Shingles virus infection
2. Treatment of genital herpes infection and suppression of recurrent genital herpes

3. Dosage and dosage
1. Treatment of shingles infection
Adults: Famciclovir is administered orally at a dose of 250 mg three times a day for 7 days. It is advisable to start treatment as soon as symptoms appear after infection.

2. Treatment of primary genital herpes infection
Adults: Administer this drug orally, 250 mg at a time, 3 times a day for 5 days. It is advisable to start treatment as soon as symptoms appear after infection.

3. Treatment of acute recurrent genital herpes infection
Adults: Administer this drug orally, 125 mg at a time, twice a day for 5 days. It is advisable to start treatment as soon as symptoms appear during the prodromal period or after infection.

4. Suppression of recurrent genital herpes
Adults: Administer this drug orally, 250 mg at a time, twice a day. Treatment is discontinued periodically every 6 to 12 months to observe changes in the natural history of the disease.

5. Patients with renal impairment: In patients with renal impairment, the creatinine clearance rate of this drug is reduced, so careful dosage adjustment is required. The dosage and directions for use are as follows.

1) Treatment of shingles and primary genital herpes infection:
Creatinine clearance: 30~59 mL/min/1.73㎡
250 mg at a time, twice a day

Creatinine clearance: 10~29mL/min/1.73㎡
250 mg each time, once a day

2) Treatment of acute recurrent genital herpes infection:
Creatinine clearance: 30~59mL/min/1.73㎡
125 mg twice a day

Creatinine clearance: 10~29mL/min/1.73㎡
125 mg once a day

3) Suppression of recurrent genital herpes infection:
Creatinine clearance: 30~59mL/min/1.73㎡
250 mg at a time, twice a day

Creatinine clearance: 10~29mL/min/1.73㎡
125 mg twice a day

4) If only serum creatinine is known, the creatinine clearance rate can be calculated using the following calculation formula.
Men: {Weight (kg) × (140-Age)}/ {72 × Serum Creatinine (mg/dL)}
Women: 0.85 × value obtained for men

5) Patients with renal impairment undergoing hemodialysis
In patients receiving hemodialysis, dosing every 48 hours is preferable, taking the dialysis schedule into account. Four hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, so administer it immediately after dialysis. The recommended dose is 250 mg for herpes zoster and 125 mg for genital herpes.

6. Patients with hepatic impairment: For patients with chronic compensated liver disease, no separate dosage adjustment is necessary. Because there is not sufficient treatment experience for patients with obvious chronic decompensated liver disease, a clear recommended dose has not been established.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its components or penciclovir, the bioactive substance of this drug
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)

2. Administer with caution to the following patients.
1) Patients with renal impairment

3. Adverse reactions
1) Headaches and nausea have been reported in clinical trials, but they were usually mild to moderate in severity, and these symptoms occurred at a similar frequency in patients treated with placebo. All other adverse reactions were added from post-marketing experience. Frequency: very common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rarely (≥1/10,000, <1/1,000) Very Rarely (<1/10,000); Marked as unknown (cannot be estimated from data).
2) Blood and lymphatic system: Thrombocytopenia occurred in rare cases. In clinical trials, reductions in white blood cells and neutrophils occurred more frequently in the treatment group than in the placebo group.
3) Mental nervous system: Very commonly headache, common dizziness, uncommon confusion and drowsiness (especially common in elderly people), rarely hallucinations.
4) Cardiac system: Rarely palpitations
5) Digestive system: Nausea, vomiting, abdominal pain, and diarrhea commonly occurred.
6) Hepatobiliary system: Abnormal liver function tests were common, and jaundice was rarely present.
7) Skin and subcutaneous tissue: Skin rash and itching commonly appeared, and less commonly, urticaria and angioedema (e.g. facial edema, eyelid edema, periorbital edema, pharyngeal edema) appeared. Severe skin reactions (e.g., erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) and leukocytoclastic vasculitis have occurred, but the frequency is unknown as the information is collected from spontaneous reports and the literature.
8) Kidney: Rarely, acute renal failure has been reported in patients with renal disease who did not reduce the dose of this drug appropriately considering renal function.
9) As a result of domestic post-marketing surveillance (number of cases: 4,304 people), the adverse reactions that occurred were as follows, and it is unclear whether they are related to this drug. : Epigastric pain, constipation, abnormal liver function, diarrhea, abdominal distension, indigestion, facial edema, fatigue, pain, leukopenia, insomnia, shortened menstrual period, difficulty urinating.

4. General precautions
1) This drug cannot completely cure genital herpes, and patients should be advised to avoid sexual contact when they have symptoms of genital herpes even after starting treatment with this drug. Additionally, because there is a possibility of infection, it is recommended to practice safe sex along with treatment with this drug. Teach patients to begin treatment immediately at the first sign or sign of recurrence.
2) There is no evidence that this drug affects the ability to drive or operate machinery. However, patients who experience dizziness, drowsiness, confusion, or other central nervous system disorders while taking this drug should refrain from driving or operating machinery.
3) For patients with mild to moderate hepatic impairment, there is no need to specifically adjust the dose if renal function is normal. Although there have been no studies on patients with severe hepatic impairment, there is a possibility that in these patients, famciclovir is not converted to the bioactive substance, penciclovir, and thus the plasma concentration of penciclovir is low, reducing the efficacy of the drug.

5. Interaction
1) Preclinical tests showed that this drug has no potential to induce cytochrome P450 or inhibit CYP3A4.
2) Effects of other drugs on this drug
- There was no clinically significant change in the pharmacokinetics of the bioactive substance penciclovir when 500 mg of this drug was administered as a single dose after administration of allopurinol, cimetidine, theophylline, zidovudine, promethazine, antacids (magnesium and aluminum hydroxide), or simultaneously with emtricitabine.
- When digoxin was administered multiple times after multiple doses of this drug (500 mg once, three times a day), no clinically significant changes in the pharmacokinetics of penciclovir were observed.
- Drugs that are primarily excreted through active renal tubular secretion (e.g. probenecid) may increase plasma penciclovir concentrations. Therefore, when patients taking 500 mg of this drug at a time, 3 times a day, take probenecid for several consecutive days, they should be monitored for toxicity, and a dose reduction of this drug may be considered.
- Penciclovir is metabolized by aldehyde oxidase, so it has the potential to induce/inhibit this enzyme or interact with other drugs that are metabolized by this enzyme. In a test to determine the clinical interaction with the in vitro aldehyde oxidase inhibitors cimetidine and promethazine, it was found that co-administration did not affect the formation of the bioactive substance penciclovir. However, ramoxifen, a strong in vitro aldehyde oxidase inhibitor, was shown to be able to reduce the formation of penciclovir, so the therapeutic effect should be monitored when this drug is used in combination with ramoxifen.
3) Effects of this drug on other drugs
- When single or multiple doses of 500 mg (500 mg once, three times a day) were administered in combination with digoxin, the pharmacokinetics of digoxin did not change.
- When a single dose of 500 mg of this drug was administered in combination with zidovudine or emtricitabine, no clinically significant effects were observed on the pharmacokinetics of zidovudine, zidovudine glucuronide, a metabolite of zidovudine, and emtricitabine.
- This drug has been shown to weakly inhibit aldehyde oxidase in vitro.

6. Administration to pregnant women, lactating women, and women of childbearing potential
1) In animal experiments, no fetal toxicity or malformations were found due to this drug or the bioactive substance penciclovir. In animal experiments, histopathological changes in the testicles were observed, but in humans, when this drug was administered at 250 mg once, twice a day for a long period of time, it had no significant effect on male sperm count, sperm shape, or motility. A decrease in reproductive performance was observed in male rats administered 500 mg/kg, but there was no significant change in reproductive performance in female rats.
2) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) Lactating women: In animal experiments using rats, penciclovir was found to be transferred into breast milk after oral administration of this drug, but there is no information on its transfer into human breast milk. It is administered to nursing mothers only when the therapeutic benefits are judged to outweigh the risks.
4) Women of childbearing potential: There is no data on women of childbearing potential, and there are no special recommendations.

7. Administration to children
Safety and effectiveness have not been established for children under 18 years of age, so it is not recommended to be administered to children under the age of 18.

8. Administration to elderly people
In general, dosage adjustment is not required in elderly people, but dosage adjustment is necessary in cases of renal impairment.

9. Treatment in case of overdose
Experience with overdose with this drug is limited. In case of overdose, provide appropriate supportive and symptomatic treatment. Hemodialysis can be performed, and the blood concentration of penciclovir, the bioactive substance of this drug, can be reduced by 75% with 4 hours of hemodialysis.

10. Precautions for storage and handling
1) Store in a dry place below 30℃.
2) Store out of reach of children.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Others
The incidence of mammary cancer increased in the high-dose group (600 mg/kg/day) in female rats administered approximately 50 times the clinical dose. When young rats were administered 0, 40, 125, or 400 mg/kg/day of famciclovir daily for 10 weeks starting from the 4th day after birth, there were no deaths or clinical observations related to the administration. There was no increased toxicity of famciclovir in young rats compared to adult animals.

5. How to save
Airtight container, stored in dry place (below 30℃)

6. Packaging unit
21 tablets/PTP

7. Expiration date
36 months

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Famclovir Tab.Palmclova tablet (ingredient name, dosage, instructions for use...2013.04.26HWPPalm Clover Tablet_Product License Changes 130426.hwp
4Famclovir Tab.Palm Clover Tablet (Precautions for use)2012.12.26HWPPalm Clover Town_Permission changes.hwp
3Famclovir Tab.Palmclova tablet (efficacy, dosage, directions for use...2008.01.02HWP9-3. Palm Clover Jeong (2008.01.02).hwp
2Famclovir Tab.Palmclova Tablet (Dosage)2008.08.26HWP9-2. Palm Clover Tablet (Dosage)(2008.08.26).hwp
1Famclovir Tab.Palm Clover Tablet (Precautions for use)2009.10.07HWP9-1. Palm Clover Tablet (Precautions for use)(2009.10.07).hwp